title: The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study.
abstract: BACKGROUND
  Combined treatment of a calcium antagonist and α/β-adrenoreceptor blocker is expected to offer some advantages in the management of hypertension; however, their antihypertensive efficacy and safety remain relatively under-explored.
  
  
  METHODS
  The current study addresses the 24-h antihypertensive efficacy and safety of arotinolol combined with a different calcium channel blocker. One-hundred fifty-two patients were randomly divided into three groups: nifedipine, amlodipine and felodipine group. In each group, the antihypertensive treatment dose was 30 mg/d, 5 mg/d, 5 mg/d long acting nifedipine, amlodipine, felodipine plus 20 mg/d arotinolol, respectively. Blood pressure was measured in ABPM devices and mercury manometer.
  
  
  RESULTS
  The result showed that the effective rate of one year antihypertensive treatment of arotinolol combined with nifedipine was 51 of 53, significantly effective (p < 0.05) among three combinations. It also showed that there was no statistical significant difference (p > 0.05) in controlled rate of morning peak blood pressure between treatment of arotinolol combined with amlodipine and arotinolol combined with nifedipine, but there was a significant difference (p < 0.01) in controlled rate of morning peak blood pressure between arotinolol combined with nifedipine vs. felodipine and arotinolol combined with amlodipine vs. felodipine.
  
  
  CONCLUSIONS
  The therapy approached of arotinolol combined with nifedipine or amlodipine could be effective and well-tolerated, and they can be used as the better chosen antihypertensive drug.
authors.affiliation: Department of Cardiology and.
authors.forename: Hong
authors.initials: H
authors.lastname: Fang
authors.forename: Wei
authors.initials: W
authors.lastname: Chen
authors.forename: Xuan
authors.initials: X
authors.lastname: Liu
authors.forename: Wenjun
authors.initials: W
authors.lastname: Xu
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage; D000368:Aged; D000369:Aged, 80 and over; D017311:Amlodipine / Q000008:administration & dosage; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D044466:Asian People; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000008:administration & dosage* / Q000009:adverse effects; D002681:China; D002940:Circadian Rhythm; D004359:Drug Therapy, Combination; D000075222:Essential Hypertension; D015736:Felodipine / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000008:administration & dosage; D011412:Propanolamines / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D011412:Propanolamines; D017311:Amlodipine; C024523:arotinolol; D009543:Nifedipine; D015736:Felodipine
keywords: calcium channel blockers; hypertension; β Blocker